Brodalumab in psoriasis: evidence to date and clinical potential
Brodalumab is a recombinant, fully human monoclonal antibody (IgG2) which binds with high affinity to the interleukin (IL) 17 receptor A (IL17R). Brodalumab is now licensed and approved for the treatment of moderate-to-severe chronic plaque psoriasis in North America and Europe. As the third to mark...
Saved in:
Main Authors: | Amy C Foulkes (Author), Richard B Warren (Author) |
---|---|
Format: | Book |
Published: |
BioExcel Publishing Ltd,
2019-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Clinical potential of brodalumab in the management of psoriasis: the evidence to date
by: Sandoval LF, et al.
Published: (2015) -
Spotlight on brodalumab in the treatment of plaque psoriasis: the evidence to date
by: Galluzzo M, et al.
Published: (2019) -
Brodalumab to the Rescue: Efficacy and Safety of Brodalumab in Patients with Psoriasis and Prior Exposure or Inadequate Response to Biologics
by: Alan Menter, et al.
Published: (2020) -
Brodalumab
by: Murat Borlu
Published: (2022) -
Brodalumab for the treatment of moderate-to-severe psoriasis: case series and literature review
by: Pinter A, et al.
Published: (2019)